These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9036301)

  • 21. Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
    Kleiman NS; Grazeiadei N; Maresh K; Taylor RJ; Frederick B; Lance ET; Effron MB; Jordan RE; Mascelli MA
    Am Heart J; 2000 Sep; 140(3):492-501. PubMed ID: 10966553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients.
    Aristides M; Gliksman M; Rajan N; Davey P
    Heart; 1998 Jan; 79(1):12-7. PubMed ID: 9505912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Acute in-stent thrombosis caused by delayed circular dissection of the right coronary artery treated with additional stent implantation and abciximab infusion].
    Pawłowski T; Kulawik T; Kwiatkowski P
    Kardiol Pol; 2006 Aug; 64(8):907-8; discussion 909. PubMed ID: 16981065
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
    Gunasekara AP; Walters DL; Aroney CN
    Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does abciximab provide long-term benefit for patients with acute myocardial infarction treated with stents?
    Neumann FJ
    Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):190-1. PubMed ID: 16568126
    [No Abstract]   [Full Text] [Related]  

  • 26. Abciximab therapy in percutaneous intervention: economic issues in the United States.
    Goklaney AK; Murphy JD; Hillegass WB
    Eur Heart J; 1998 Apr; 19 Suppl D():D52-8. PubMed ID: 9597522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variability in abciximab (ReoPro) prescribing: evidence based or budget driven?
    Zwart-van Rijkom JE; Leufkens HG; Simoons ML; Broekmans AW
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):135-41. PubMed ID: 11998538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seeing is believing.
    White CJ
    Cathet Cardiovasc Diagn; 1997 Oct; 42(2):185-6. PubMed ID: 9328704
    [No Abstract]   [Full Text] [Related]  

  • 29. Abciximab provides cost-effective survival advantage in high-volume interventional practice.
    Kereiakes DJ; Obenchain RL; Barber BL; Smith A; McDonald M; Broderick TM; Runyon JP; Shimshak TM; Schneider JF; Hattemer CR; Roth EM; Whang DD; Cocks D; Abbottsmith CW
    Am Heart J; 2000 Oct; 140(4):603-10. PubMed ID: 11011333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of intravenous abciximab as adjunctive therapy for carotid angioplasty and stent placement.
    Arab D; Yahia AM; Qureshi AI
    Int J Cardiovasc Intervent; 2003; 5(2):61-6. PubMed ID: 12745860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
    Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
    Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using cost-effectiveness for subsidy decisions.
    Glasziou P
    Heart; 1998 Jan; 79(1):7-8. PubMed ID: 9505908
    [No Abstract]   [Full Text] [Related]  

  • 34. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
    Schömig A; Schmitt C; Dibra A; Mehilli J; Volmer C; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Berger PB; Kastrati A;
    Eur Heart J; 2005 Jul; 26(14):1379-84. PubMed ID: 15734767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
    Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Berger PB; Schömig A
    Eur Heart J; 2008 Feb; 29(4):455-61. PubMed ID: 18158289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coronary artery stenting during acute myocardial infarction in patients treated with IIb/IIIa anti-platelet antibodies: early outcome results.
    Murdock DK; Hoffman MT; Logemann TN; Kaufman JS; Engelmeier RS
    Wis Med J; 1996 Dec; 95(12):867-71. PubMed ID: 8993226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lysis of intracoronary thrombus prior to coronary stenting using the dispatch infusion catheter.
    Satler LF; Mintz GS
    Cathet Cardiovasc Diagn; 1996 Aug; 38(4):415-6. PubMed ID: 8853155
    [No Abstract]   [Full Text] [Related]  

  • 39. AIDA STEMI: no benefit for intracoronary abciximab.
    Bertrand OF; Jolly S
    Lancet; 2012 Mar; 379(9819):875-877. PubMed ID: 22357108
    [No Abstract]   [Full Text] [Related]  

  • 40. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial.
    Marzocchi A; Manari A; Piovaccari G; Marrozzini C; Marra S; Magnavacchi P; Sangiorgio P; Marinucci L; Taglieri N; Gordini G; Binetti N; Guiducci V; Franco N; Reggiani ML; Saia F;
    Eur Heart J; 2008 Dec; 29(24):2972-80. PubMed ID: 18940887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.